Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study-Reference-Cited by-同舟云学术

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:10140-10141
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bumma Naresh¹,Richter Joshua²,Brayer Jason³,Zonder Jeffrey A.⁴,Dhodapkar Madhav⁵,Shah Mansi R.⁶,Hoffman James E.⁷,Mawad Raya⁸,Maly Joseph J.⁹,Lentzsch Suzanne¹⁰,Suvannasankha Attaya¹¹,Roy Pourab¹²,Dey Jyotirmoy¹²,Chokshi Dhruti¹²,Boyapati Anita¹²,Visich Jenn¹²,Houvras Yariv¹²,Rodriguez Lorenc Karen¹²,Kroog Glenn S.¹²,Jagannath Sundar²

Affiliation:

1. 1The Ohio State University Comprehensive Cancer Center, Columbus, OH

2. 2Icahn School of Medicine at Mount Sinai, New York, NY

3. 3H. Lee Moffitt Cancer Center, Tampa, FL

4. 4Karmanos Cancer Institute, Wayne State University, Detroit, MI

5. 5Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

6. 6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

7. 7University of Miami Health System, Miami, FL

8. 8Swedish Center for Blood Disorders and Cellular Therapy, Seattle, WA

9. 9Norton Cancer Institute, Louisville, KY

10. 10Columbia University Medical Center, New York, NY

11. 11Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN